⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IKT News
Inhibikase Therapeutics, Inc. Common Stock
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
IKT
Form 8-K
sec.gov
IKT
Form 8-K
sec.gov
IKT
Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity
globenewswire.com
IKT
Form 8-K
sec.gov
IKT
Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension
globenewswire.com
IKT
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
IKT
Form 8-K
sec.gov
IKT
Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity
globenewswire.com
IKT
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
globenewswire.com
IKT